



Covid-19, vacunas y la UE

DG Health and Food Safety (SANTE)

Isabel de la Mata

Principal Advisor

Health and crisis management

February 25th 2021



“

We can only be safe if everyone in Europe has access to the vaccine, including our neighbouring countries.

No country in Europe can move forward without the others.

It is only together that we can overcome this profound health emergency and economic crisis.

EU role in vaccination for COVID-19

- Public health policy is a Member State competence
- Exceptions for cross border health threats where legislation exists (surveillance, alert, risk assessment and risk management coordination)
- EU pharmaceutical legislation for evaluation and authorisation of medicines including vaccines
- Supported by several EU agencies (EMA and ECDC)



Vaccine Strategy

The European Vaccine Strategy aims to

- secure the **production of vaccines** within the EU
- ensure sufficient supplies for our Member States through **Advance Purchase Agreements** with vaccine producers
- adapt the **EU's regulatory framework** to the current emergency
- use the **flexibility of our rules** to speed up the development, authorisation and availability of vaccines

Key actions to date

European Vaccines Strategy

17
June

Communication on preparedness for COVID-19 vaccination strategies and deployment

15
Oct

By this date, **6 contracts** with potential vaccine producers are in place

25 Nov

17 Dec

Concludes talks with **Novavax** for potential 200 million doses

21 Dec

Commission approves **BioNTech-Pfizer** vaccine

27, 28,
29/12

EU **Vaccination Days** start

6 Jan

Commission approves **Moderna** vaccine

8 Jan

300 million additional doses of BioNTech-Pfizer vaccine

12 Jan

Concludes talks with **Valneva** for potential 60 million doses



Working closely with Member States

- Our Vaccine strategy should act as a **reference point for Member States** when formulating their national strategies
- People can be vaccinated according to national **vaccine programmes**
- The Commission **supports EU countries** in the preparation and implementation of their vaccine campaigns, including via communication material
- The Commission also put in place a common **reporting framework** and a **platform** to monitor the effectiveness of national vaccine strategies

Vaccine doses secured


- The Commission has secured up to **2.6bn vaccine doses** so far:
- BioNTech-Pfizer: 600 million doses
- Moderna: 460 million doses
- CureVac: 405 million doses
- AstraZeneca: 400 million doses
- Johnson&Johnson: 400 million doses
- Sanofi-GSK: 300 million doses




Vaccination strategies

- All Member States have access to COVID-19 vaccines at the same time
- Distribution done on a per capita basis to ensure fair access
- National vaccination strategies and priority groups
- 19 January 2021: Communication calling on Member States to speed up the roll out of vaccines across the EU.
- **Objectives:** By March 2021, at least 80% of people over the age of 80, and 80% of health and social care professionals in every Member State should get vaccinated.
By summer 2021, Member States should have vaccinated a **minimum of 70% of the entire adult population**

The COVID-19 Vaccine tracker by the ECDC



The COVID-19 Vaccine tracker by the ECDC



The COVID-19 Vaccine tracker by the ECDC

Cumulative uptake (%) of the first vaccine dose among adults (18+) in EU/EEA countries as of 2021-04-12



Uptake first dose (%)


Not Reported

32.6%


Cumulative uptake first dose among adults (18+) in EU/EEA	Cumulative uptake full vaccination among adults (18+) in EU/EEA
16.5%	6.8%
Cumulative Uptake from 29 reporting countries	Cumulative Uptake from 29 reporting countries

Cumulative uptake (%) of the first vaccine dose among adults (18+) in EU/EEA countries as of 2021-04-12

by reporting week




Progress in the vaccine uptake among adults (18+) in EU/EEA countries as of 2021-04-12



Cumulative uptake (%) of the first vaccine dose and full vaccination among adults (18+) in EU/EEA countries as of 2021-04-12

Bubble size: Total dose administered



Global response



CORONAVIRUS GLOBAL RESPONSE

Commission launches **Coronavirus Global Response** in May 2020 to mobilise funds for research and development of tests, treatments and vaccines, strengthen health systems and the global recovery

close to **€16 billion**
pledged

ACT-ACCELERATOR

The Access to COVID-19 Tools Accelerator was launched at the end of April 2020 by the WHO, the EU and global health organizations to:

- Accelerate development of COVID-19 vaccines, tests and treatments
- Ensure equitable global access
- Strengthen health systems

ACT-A brings together governments, scientists, civil society, charities and global health organizations.

€9.1 billion
pledged

Global response

COVAX

Vaccine pillar of ACT-A, co-led by Gavi, the Vaccine Alliance, CEPI and WHO

€5.18 billion
pledged

Over €2.2 billion
from the EU's TEAM EUROPE

brings us closer to COVAX's objective to deliver at least 1.3 billion doses for lower income countries by end of 2021



Global response

Last update: 12 April 2021



Webtools | [Leaflet](#) | © OpenStreetMap contributors | [Disclaimer](#)

Global response



EU VACCINE-SHARING MECHANISM

- Will allow 27 Member states to share EU purchased doses with third countries, including through COVAX
- EU has secured 2.6 billion doses from six vaccine producers for Europe, with the possibility to share with other countries, in particular the Western Balkans, the EU's Neighbourhood and Africa



STRENGTHEN HEALTH SYSTEMS

- We need to make progress with global vaccination and prepare health systems for future pandemics, especially in the most vulnerable countries
- EU has invested over €1.1 billion to strengthen health systems in 13 African countries: Burkina Faso, Burundi, Central African Republic, Democratic Republic of Congo, Ethiopia, Guinea (Conakry), Guinea Bissau, Libya, Mauritania, Morocco, Nigeria, Sudan, Zimbabwe

Global response

- EUCO 23.3: The European Union will continue to strengthen its global response to the pandemic. Work on setting up a vaccine-sharing mechanism must be taken forward rapidly so as to complement and support COVAX's leading role in ensuring universal access to, and deployment of, vaccines.
- Global Health Summit, Rome, 21 May 2021. G20 Leaders, International and regional organisation heads and representatives of global health bodies will share lessons learned from the pandemic and agree principles supporting further cooperation and joint action preventing future global health crisis, irrespective of origin and in spirit of solidarity